Cochlear’s ASX Growth Plans Face Execution Test as Profit Outlook Holds Steady

Highlights

• FY2027 underlying profit guidance remains AU$330 million–AU$350 million following a challenging year.
• Nexa exceeded 95% of developed-market implant sales by June, supporting higher pricing.
• Referral expansion and implant innovation underpin efforts to reach more eligible adults.

Cochlear Limited (ASX: COH) outlined its growth priorities in its annual general meeting addresses released on 26 October 2026, with its shares at a current market price of AU$144.80, down 1.4%. The hearing implant manufacturer maintained its earnings outlook, leaving investors assessing whether product innovation and tighter execution can strengthen performance.

Profit Outlook Holds Steady

Cochlear reaffirmed FY2027 underlying net profit guidance of AU$330 million to AU$350 million, unchanged from August.

FY2026 sales revenue reached AU$2.3 billion, increasing 2% in constant currency, while underlying net profit totalled AU$322 million. Earnings missed initial expectations but finished near the top of April’s revised guidance. Revenue growth improved during the second half.

European healthcare capacity constraints and industrial action, US insurance delays, Chinese reimbursement changes, Middle East disruption and currency headwinds weighed on performance.

Nexa Gains Commercial Traction

By June, Nexa accounted for more than 95% of implant sales in developed markets, alongside an average price increase of 3%. Its upgradeable technology also supports future implant development.

Cochlear has invested approximately 12% of annual sales in research and development for more than 40 years.

Pivotal studies for its drug-eluting electrode are complete, with results being analysed before subsequent regulatory steps. Recruitment has also concluded for pivotal studies of its totally implantable cochlear implant, designed to operate without an external sound processor. Recipients have accumulated over 1,000,000 hours using the technology.

Expanding Access Remains Crucial

Cochlear supported more than 55,000 implant recipients in FY2026, estimating lifetime net societal benefits exceeding AU$9 billion.

Nevertheless, fewer than 5% of eligible adults receive implants. Clinical practice guidelines are being implemented across 25 countries to improve treatment pathways.

Its team serves more than 180 countries, while employee engagement remained above 80%.

Outlook

Cochlear’s priorities include reducing fixed costs, strengthening medical referrals and expanding adoption of products such as Osia 3. Its reaffirmed guidance provides an earnings benchmark, while sustained improvement will depend on converting unmet patient need into treatment and managing operating pressures.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au